MTAP and large cell neuroendocrine carcinoma: In the MTAP‐lost NSCLC cohort, 59% were adenocarcinomas (LUAD) (12% MTAP loss), 22% were squamous cell carcinomas (LUSC) (14% MTAP loss), 16% were NSCLC not otherwise specified (NOS) with genomic profiles most consistent with LUAD (14% MTAP loss), 1% were large cell neuroendocrine carcinomas (LNEC) (9% MTAP loss), 1% were sarcomatoid carcinomas (SRC) (23% MTAP loss), and 1% were adenosquamous carcinomas (LUAS) (21% MTAP loss).